Gamco Investors INC. ET AL Takes Position in Evolent Health, Inc (EVH)

Gamco Investors INC. ET AL acquired a new stake in Evolent Health, Inc (NYSE:EVH) in the third quarter, according to its most recent filing with the SEC. The fund acquired 75,003 shares of the technology company’s stock, valued at approximately $1,335,000. Gamco Investors INC. ET AL owned approximately 0.11% of Evolent Health at the end of the most recent quarter.

A number of other institutional investors have also added to or reduced their stakes in the stock. JPMorgan Chase & Co. boosted its holdings in Evolent Health by 7.5% in the 2nd quarter. JPMorgan Chase & Co. now owns 5,438,126 shares of the technology company’s stock valued at $137,857,000 after purchasing an additional 379,185 shares during the period. Stifel Financial Corp bought a new stake in shares of Evolent Health during the 2nd quarter worth $425,000. Edmond DE Rothschild Holding S.A. raised its position in Evolent Health by 6.9% in the 2nd quarter. Edmond DE Rothschild Holding S.A. now owns 387,000 shares of the technology company’s stock worth $9,810,000 after purchasing an additional 25,000 shares during the period. Fox Run Management L.L.C. purchased a new position in Evolent Health in the 2nd quarter worth $363,000. Finally, American Century Companies Inc. raised its position in Evolent Health by 78.4% in the 2nd quarter. American Century Companies Inc. now owns 289,226 shares of the technology company’s stock worth $7,332,000 after purchasing an additional 127,110 shares during the period. Institutional investors and hedge funds own 92.74% of the company’s stock.

A number of equities analysts recently commented on the stock. Goldman Sachs Group, Inc. (The) cut shares of Evolent Health from a “conviction-buy” rating to a “buy” rating in a research report on Tuesday, November 7th. SunTrust Banks, Inc. reiterated a “buy” rating and issued a $30.00 target price on shares of Evolent Health in a research report on Friday, November 3rd. Cantor Fitzgerald restated a “buy” rating and issued a $30.00 price objective on shares of Evolent Health in a research report on Thursday, November 2nd. Robert W. Baird restated a “buy” rating and issued a $25.00 price objective on shares of Evolent Health in a research report on Wednesday, November 1st. Finally, Zacks Investment Research upgraded shares of Evolent Health from a “sell” rating to a “hold” rating in a research report on Monday, October 9th. Two analysts have rated the stock with a sell rating, one has issued a hold rating and thirteen have given a buy rating to the stock. The company currently has an average rating of “Buy” and an average target price of $28.70.

Evolent Health, Inc (NYSE EVH) opened at $11.45 on Tuesday. Evolent Health, Inc has a 52-week low of $10.35 and a 52-week high of $27.50. The company has a debt-to-equity ratio of 0.11, a quick ratio of 3.34 and a current ratio of 3.34.

Evolent Health (NYSE:EVH) last announced its quarterly earnings results on Thursday, November 2nd. The technology company reported ($0.04) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.08) by $0.04. Evolent Health had a negative net margin of 15.86% and a negative return on equity of 5.05%. The company had revenue of $107.90 million for the quarter, compared to analysts’ expectations of $104.49 million. During the same quarter in the previous year, the company earned ($0.26) earnings per share. Evolent Health’s quarterly revenue was up 79.2% on a year-over-year basis. equities analysts expect that Evolent Health, Inc will post -0.57 earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: This report was first published by TrueBlueTribune and is the sole property of of TrueBlueTribune. If you are viewing this report on another website, it was copied illegally and reposted in violation of U.S. and international copyright and trademark law. The original version of this report can be read at https://www.truebluetribune.com/2017/11/14/gamco-investors-inc-et-al-takes-position-in-evolent-health-inc-evh.html.

Evolent Health Company Profile

Evolent Health, Inc is engaged in healthcare delivery and payment. The Company supports health systems and physician organizations in their migration toward value-based care and population health management. The Company provides an end-to-end, technology-enabled services platform for providers. The Company’s platform, powered by its technology, processes and integrated services, enables providers to migrate their economic orientation from fee-for-service (FFS) reimbursement to payment models that reward value-based payment models.

Institutional Ownership by Quarter for Evolent Health (NYSE:EVH)

Receive News & Ratings for Evolent Health Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolent Health Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply